OA10976A - Pharmaceutical compositions of corticotropin releasing hormone antagonists - Google Patents
Pharmaceutical compositions of corticotropin releasing hormone antagonists Download PDFInfo
- Publication number
- OA10976A OA10976A OA9900034A OA9900034A OA10976A OA 10976 A OA10976 A OA 10976A OA 9900034 A OA9900034 A OA 9900034A OA 9900034 A OA9900034 A OA 9900034A OA 10976 A OA10976 A OA 10976A
- Authority
- OA
- OAPI
- Prior art keywords
- dimethyl
- phenoxy
- ethyl
- trimethyl
- propoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (30)
19 a ...... V. i il*Zi Îad&'jwJ) 310976 10 15 20 25
1. Use of 4-{l-ethyl-propoxy)-3,6-dimethyl-2-(2.4,6-tnmeTnyl-pnenoxy)-pynaîneor (3,6<J!Œetfiyl-2’(2AS<rin39inyl^h?noxy^pyrid:n>4-ylH'l-etnyl-propyl)-arri!ne, a prodrugthereof nr a pharmaceutlcaliy acceptable sait thereof or cf said prodrug «n tne manufactureof a médicament for treating heart faillira in a msmmal.
2. A use of claim 1 wherein 4-(l-etnyl-propûxy)-3,6-dimethyl-2-(2.4,6-tnmethyl-phenoxyj-pyndine or a pharmaceuticaiiy acceptable sait thereof is administered.
3. A use of daim 2 whsrein 4-(1-ethyl-propoxy>«3.6’dimethyi-2-(2,4.6-trimethyl-phencxybpyrfdlne is adminstered.
4. A use of claim 2 wh.erein the mammal is a human. 5 A use of claim 2 whsrem tns mammal Is a compariicn animal.
5. A use cf daim 2 wherein me nean faüure is congestive heart failure.
7. A use of claim 6 wherein 4-(t-e!nyl-propoxy)-3,6*dlm2thyl-2-(2,4,e-tnmeîhyÎ- pnenoxyj-pyridme js adminstered. Ô. A use of daim o wherein the mammal i3 a human. U. A use of claim 8 wherein the congestive heart failure does not worsen.
10. A usg of ciairn G wnerein tne rnammai is a companion animal.
11. A use cf daim 1 wherein (3,C>dimetnyl-2’(2,4.6-trlinethyl-pnenoxy)'pyriOin-4>ytj-(1-emyi-propyi)»amine or a pharmaceuticaily acceptable sait thereof is administered.
12. A use of claim Π wherein (3,S’û’imethyl-2-(2,4,6-trimemyl-phenûxy)-pyridiÎ>4-y 1)-(1-othyl-prcpy!)-amine is administered.
13. A use of claim 11 wnerein the mammal is a human.
14. A use of daim 11 wherein the mammal is a companion animal.
15. A use of daim 11 wherein the heart failure is congestive heart failure.
16. A use of daim 15 wnerein (3,6-dimethyl-2-(2,4,6'trimewyl-phenûxy?pyridJn·4-yl.K1-ethyI-propyl)-amine is administered.
17. A use of daim 15 wherein the mammal is a human.
18. Λ use of ciairn 17 wherein the congestive heart failure does not worsen.
19. Λ use of claim 15 wherein the mammal is a companion animal.
20. A pharmaccutical composition comprising (a) 4-{1 -etnyl-prcpcxy}-3.5-dim3myt-2-(2A8’thmGthyl~pnenûXy)-pyriaine or (3,<3*dimcîhyl-2-(2,4.6‘trimaihyl-phenoxy)- pyndin-T’yiHl-ethyi-propcxy)-am:n9, a prodrug tr *rcof or a pharmsccuiically acceptable sait thereof or of sa-.d prodrug, (h) a cangss'iva heart tailuro treeting agent and iC) apharmcoeutically acceptable carrier or diluent. 30 ι>·ι> i ju ι. umju; J «,. 4 x A
w 010976
21. A pnarmacauticai composition cf daim 20 wherein said congestive heartfaiiure treating agent is a cardiac glycoside, a toop diuretic, a thiazide diuretic, a potassiumion sparing diuretic, an angiotensin convertlng enzyme ïnnifcntor, en angtotansion receptorantagonist, a nitrovasodiiaior, a pnosphodiesterase înnipitor. a direct vasodilator, an o,-adrenergic receptor antagonisb a calcium channel blocker or a sympathomimetic agent
22. A pharmaceutical composition of daim 21 comprising 4-(1-ethyl-pnopoxy>-3,Q-dÎmeihyl-2-(2,4.6-trimethyl-phenoxy)«pyridÎne. 23. a pharmoceutical composition of daim 22 comprising 4-(1-ethyl-propoxy}- S.S-dimstnyi^-fSAB-trimethyl-phenoxyJ-pyridine.
24. Λ pharmaceutical composition of daim 23 wherein said calcium channelPlocxor Is amlcdipine. 15 20 25 30 35 25. a pharmaceutical composition of daim 21 comprising (3.6-dimethyf-2-(2,4,6-trÎmethyi-pnenaxy}’pyridin-4'yi)-{l-ethyi-propoxy)-aminG or a pharmaceutically acceptablesait thereof.
20. A pharmaceutical composition of daim 25 comprising (3,G-dimethyl-2-{2.4.6-trimetfiyl-plienoxy}-pyridin-4-y()’( 1 -ethyi-prapoxy)-amlne.
27. A pharmaceutical composition of daim 26 wherein said calcium channelblocker is emiodipina. 28. usa of a pnarmnccutical composition of claim 20 in the manufacture of ameaicament for treanng neart faiiure în a mammai.
29. A usa of daim 28 wherein said congestive heart faiiure treating agent îa acardiac glycoside. a loop diuretic. a thiazide diuretic, a potassium ion spanng diuretic. ansngiotensin convertmg enzyme inhibitor, an angiotension receptor antagonist, ar.iîrovascdilator, a phosphodiesterase inhibitor, a direct vasodilator, an α,-adrenergjcreceptor antagonist, a calcium channel docker or a sympathomimetic agent.
30. Λ use cf daim 29 comprif’ng 4<1-eihyl^repoxy)<3,8<imethyl-2-(2,4,i>·trimethyl-pnenoxyj-pyn’dine or a pharmncouticslly acceptable sait thereof.
31. A use of daim 30 wnsrein the mesylata sait of 4-{1-ethy!-propcxy)-3,6-cimethyl-2«(2,4,6-trimethy,'--:.',snoxy)'py.'.’ t:nc is adminriered. 32 λ usa cf ciîiim 31 wherein said calcium ^harintii blocker is amlc-.pmo.
33. A use of claim 29 comprising (3,S<timethyl-2-{2,4.G4r;methyl^henoxy)-pyriûin- T-yO-(i-ethy|-prcpoxy)-amine or a pharmaceuticaily acceptable sait thereof.
34. A usa of claim 33 wherein (3,6-dimeinyl-2-(2,4,8-trirnetny!-phenoxy}-pyn‘d:h·a-yi?-(1'-athyl-prcpoxy)-am!ne is aûministered. 05. a usa of claim 34 v srem said calcium channel blocker is amlodipina. 21 010976
38. A kit compneing a. an amount of a compound, said compound bemg seleoed front 4-{1-ethyl‘propoxy)-3,6-dimethyl-2-(2,4.8-trimetnyl-pnenoxy>pyrtdine, (3,6ΌίτηΒΐηγΙ-2-{2Α6-trimethyl-pnenoxyJ-pyridin-4-yij-(i-etnyl-propoxyj-amine, a prodrug theraof, and a 5 pnarmaceuticajiy acceptante sait of said compound or said tait în a finît unit dosage form; b- an amount Qf a congestive heart failura treating agent; and c, a container. 37 A kit of daim 36 wnerein said congestive neart failure treating agent is acaraiac glycosïde, a loop diuretic. a thiaziûe diuretic, a potassium ion spanng diuretic, an 10 «ngloiensm convertîng enzyme înhibitor, an angioterttion receptor antagonlst, a nltrovasodiiator, a phasphodiesterase înhibitor, a direct vasodiiator, an a,-adrenerg»crecaptor antagomst, a calcium channel biocker or a sympathomimetic agent
38. A kit of claim 37 compflsinq 4-(1-eW-pr0p0XY}-3,8-dimethyl-2-{2,4,6-trimethyl-phenoxyj-pyridlne or a pharmaceuticaiiy acceptable sait tnereof. 15 39. A kit of claim 38 wherem 4-(i-etnyi-pfôpaxy)-3,e-dimeinyi-2-(2,4.6-tnmetnyl- phenoxyhpyndine ia administared.
40. A kit of cjaim 39 wherein said calcium channel Olocker is amlodipin·.
41. A kit of daim 40 comprising (3(6'dimetbyl-2-(2A0-tnmewyhpnenoxy)-pyrtdin-4-y l}-{1 -eihyi-propûxy)-arnine. 20 42. A kit of claim 41 wherem O.e-dimettiyl^-iS^.â-trimethyl-phenoxyhpyriain-l- yi)-(i-etnyl-propoxy)-amine is adrïtfnistered.-
43. A kit of daim 42 wherem said calcium channel docker is amlodipine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7493498P | 1998-02-17 | 1998-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10976A true OA10976A (en) | 2001-11-05 |
Family
ID=22122537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9900034A OA10976A (en) | 1998-02-17 | 1999-02-16 | Pharmaceutical compositions of corticotropin releasing hormone antagonists |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6043260A (fr) |
| EP (1) | EP0951906A1 (fr) |
| JP (1) | JPH11292766A (fr) |
| KR (1) | KR19990072616A (fr) |
| CN (1) | CN1231176A (fr) |
| AP (1) | AP9901464A0 (fr) |
| AR (1) | AR017723A1 (fr) |
| AU (1) | AU1732999A (fr) |
| BG (1) | BG103180A (fr) |
| BR (1) | BR9900653A (fr) |
| CA (1) | CA2262252C (fr) |
| EA (1) | EA199900124A3 (fr) |
| GT (1) | GT199900015A (fr) |
| HR (1) | HRP990054A2 (fr) |
| HU (1) | HUP9900386A3 (fr) |
| ID (1) | ID23218A (fr) |
| IL (1) | IL128531A0 (fr) |
| IS (1) | IS4975A (fr) |
| MA (1) | MA26608A1 (fr) |
| NO (1) | NO990722L (fr) |
| OA (1) | OA10976A (fr) |
| PA (1) | PA8467401A1 (fr) |
| PE (1) | PE20000266A1 (fr) |
| PL (1) | PL331507A1 (fr) |
| SG (1) | SG81261A1 (fr) |
| TN (1) | TNSN99024A1 (fr) |
| TR (1) | TR199900328A2 (fr) |
| ZA (1) | ZA991220B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US6387894B1 (en) * | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
| AU7604400A (en) | 1999-09-21 | 2001-04-24 | Emory University | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| KR20020063934A (ko) * | 2000-01-18 | 2002-08-07 | 화이자 프로덕츠 인코포레이티드 | 코르티코트로핀 방출 인자 길항제 |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| US7015229B2 (en) | 2002-02-22 | 2006-03-21 | Pfizer Inc | Substituted pyrimidinones and pyrimidinthiones |
| AU2003220190A1 (en) * | 2002-03-13 | 2003-09-29 | Pharmacia & Upjohn Company Llc | Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators |
| JP2005533014A (ja) * | 2002-04-26 | 2005-11-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 置換ピラジン誘導体 |
| JP2006506350A (ja) * | 2002-09-12 | 2006-02-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 置換１，４−ピラジン誘導体 |
| AR041470A1 (es) * | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
| EP1565454A1 (fr) * | 2002-11-21 | 2005-08-24 | Pharmacia & Upjohn Company LLC | Composes de pyrazine en tant que modulateurs de crf |
| BRPI0409649A (pt) * | 2003-04-23 | 2006-04-25 | Pharmacia & Upjohn Co Llc | pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf |
| MXPA05011993A (es) * | 2003-05-07 | 2006-02-02 | Pharmacia & Upjohn Co Llc | Compuestos de pirrolo[1,2-b]piridazina. |
| EP1625125A1 (fr) * | 2003-05-09 | 2006-02-15 | Pharmacia & Upjohn Company LLC | Composes utilises comme antagonistes du recepteur de type 1 de la corticoliberine (crf) |
| MXPA05012081A (es) * | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Co Llc | Derivados de pirimidina sustituidos. |
| EP1626965A1 (fr) * | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Company LLC | Pyrazinones a titre d'antagonistes du recepteur de crf1 dans le traitement des troubles du systeme nerveux central |
| WO2005089639A2 (fr) * | 2004-03-16 | 2005-09-29 | Talarico M D Matthew T | Procede de deregulation vasculaire |
| US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| EP0795327A1 (fr) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique |
-
1999
- 1999-01-18 PA PA19998467401A patent/PA8467401A1/es unknown
- 1999-02-02 GT GT199900015A patent/GT199900015A/es unknown
- 1999-02-10 US US09/248,073 patent/US6043260A/en not_active Expired - Fee Related
- 1999-02-10 SG SG9900526A patent/SG81261A1/en unknown
- 1999-02-11 EP EP99301006A patent/EP0951906A1/fr not_active Withdrawn
- 1999-02-11 CN CN99102122A patent/CN1231176A/zh active Pending
- 1999-02-11 IS IS4975A patent/IS4975A/is unknown
- 1999-02-11 AP APAP/P/1999/001464A patent/AP9901464A0/en unknown
- 1999-02-12 KR KR1019990004934A patent/KR19990072616A/ko not_active Ceased
- 1999-02-12 PE PE1999000127A patent/PE20000266A1/es not_active Application Discontinuation
- 1999-02-12 BR BR9900653-7A patent/BR9900653A/pt not_active Application Discontinuation
- 1999-02-15 CA CA002262252A patent/CA2262252C/fr not_active Expired - Fee Related
- 1999-02-15 ID IDP990113D patent/ID23218A/id unknown
- 1999-02-15 IL IL12853199A patent/IL128531A0/xx unknown
- 1999-02-16 NO NO990722A patent/NO990722L/no unknown
- 1999-02-16 BG BG103180A patent/BG103180A/bg unknown
- 1999-02-16 AR ARP990100619A patent/AR017723A1/es unknown
- 1999-02-16 JP JP11037464A patent/JPH11292766A/ja active Pending
- 1999-02-16 TR TR1999/00328A patent/TR199900328A2/xx unknown
- 1999-02-16 ZA ZA9901220A patent/ZA991220B/xx unknown
- 1999-02-16 HU HU9900386A patent/HUP9900386A3/hu unknown
- 1999-02-16 TN TNTNSN99024A patent/TNSN99024A1/fr unknown
- 1999-02-16 EA EA199900124A patent/EA199900124A3/ru unknown
- 1999-02-16 MA MA25465A patent/MA26608A1/fr unknown
- 1999-02-16 OA OA9900034A patent/OA10976A/en unknown
- 1999-02-16 AU AU17329/99A patent/AU1732999A/en not_active Abandoned
- 1999-02-17 HR HR60/074,934A patent/HRP990054A2/hr not_active Application Discontinuation
- 1999-02-17 PL PL99331507A patent/PL331507A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL331507A1 (en) | 1999-08-30 |
| IL128531A0 (en) | 2000-01-31 |
| ID23218A (id) | 2000-03-30 |
| AR017723A1 (es) | 2001-09-12 |
| IS4975A (is) | 1999-08-18 |
| BG103180A (bg) | 1999-09-30 |
| AU1732999A (en) | 1999-09-02 |
| PA8467401A1 (es) | 2000-09-29 |
| SG81261A1 (en) | 2001-06-19 |
| PE20000266A1 (es) | 2000-04-07 |
| TR199900328A2 (xx) | 1999-10-21 |
| BR9900653A (pt) | 2000-10-17 |
| CA2262252C (fr) | 2006-01-10 |
| TNSN99024A1 (fr) | 2005-11-10 |
| HRP990054A2 (en) | 2000-02-29 |
| JPH11292766A (ja) | 1999-10-26 |
| HUP9900386A2 (hu) | 1999-11-29 |
| AP9901464A0 (en) | 1999-03-31 |
| NO990722L (no) | 1999-08-18 |
| ZA991220B (en) | 2000-08-16 |
| NO990722D0 (no) | 1999-02-16 |
| CA2262252A1 (fr) | 1999-08-17 |
| HU9900386D0 (en) | 1999-04-28 |
| KR19990072616A (ko) | 1999-09-27 |
| EA199900124A2 (ru) | 1999-08-26 |
| EA199900124A3 (ru) | 1999-12-29 |
| US6043260A (en) | 2000-03-28 |
| EP0951906A1 (fr) | 1999-10-27 |
| MA26608A1 (fr) | 2004-12-20 |
| HUP9900386A3 (en) | 1999-12-28 |
| CN1231176A (zh) | 1999-10-13 |
| GT199900015A (es) | 2000-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA10976A (en) | Pharmaceutical compositions of corticotropin releasing hormone antagonists | |
| EP0233461B2 (fr) | 2-Pyrimidinamines substituées en 4,5 et 6 | |
| TWI458719B (zh) | 非核苷反轉錄酶抑制劑 | |
| EP1399423B1 (fr) | Amides d'acide anthranilique comportant une chaine laterale heteroarylsulfonyle, procede de fabrication, utilisation en tant qu'agent pharmaceutique ou diagnostique, et preparations pharmaceutiques contenant ces amides | |
| JPS62281858A (ja) | ピペリジン誘導体及びその類縁誘導体 | |
| DE60313350T2 (de) | Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer | |
| KR100817443B1 (ko) | 비 효소성 당화를 예방하고 당화 관련 병변의 치료에사용될 수 있는 알부민 결합 화합물 | |
| WO2006042638A1 (fr) | Derives de 5-arylamino-1h-pyridine-2-on substitues sur 3,6 et composes similaires utilises en tant qu'inhibiteurs de la polymerase poly (adp-ribose) destines au traitement de maladies ou de lesions tissulaires provoques par une necrose ou une apoptose | |
| US20120309786A1 (en) | 3-amino-pyridine derivatives for the treatment of metabolic disorders | |
| TWI435871B (zh) | 苯基咪唑化合物 | |
| JP2010522168A (ja) | 鉱質コルチコイドレセプターモジュレータ | |
| TW445251B (en) | Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them | |
| JPH0699309B2 (ja) | 離脱症候群関連障害治療用医薬製品 | |
| DE60221152T2 (de) | Diaryl-1,2,4-triazolderivate als hochselektive cyclooxygenase-2-inhibitoren | |
| US5534532A (en) | Aliphatic amino bis-aryl squalene synthase inhibitors | |
| JPH072737B2 (ja) | ５−リポキシゲナ−ゼ経路の抑制 | |
| WO2007085203A1 (fr) | Nouveaux composés azahétérocycliques pentabasiques et utilisation de ces derniers dans le traitement de maladies liées au vieillissement des protéines | |
| CZ51399A3 (cs) | Farmaceutická kompozice a kit | |
| JP2002155060A (ja) | イミダゾール化合物及びその用途 | |
| KR101128372B1 (ko) | 1ｈ-피리딘-2-온 유도체 | |
| KR101137168B1 (ko) | 피롤로［２,３-ｄ］피리다진 유도체 및 그의 제조방법 | |
| JPS635082A (ja) | ベンズイミダゾ−ル、その製法および胃酸分泌抑制剤としての処方物 | |
| JPH0770083A (ja) | イミダゾール誘導体を有効成分とする血圧降下剤 | |
| JPH02142797A (ja) | チアゾロトリアゾール化合物 | |
| WO2002002553A1 (fr) | Compositions pharmaceutiques destinees au traitement de la nephropathie diabetique |